Insights

Somewhere in the patent office’s public records, there is a graveyard. It has no physical address and no memorial plaques, […]

Pharmaceutical executives are losing control of their product narratives. While marketing teams focus on search engine optimization and field sales,

Pfizer’s finance team did not need a news alert to know Lipitor was in trouble. By 2010, the company’s own

Reliable pharmaceutical market forecasting requires moving beyond a simple reading of the FDA Orange Book. Investors and analysts frequently treat

A deep-dive into the economics, IP strategy, and competitive dynamics shaping two divergent paths for branded generic pharmaceutical companies The

The pharmaceutical industry operates on a model where the expiration of a primary patent is no longer the end of

The Cliff Is Real, and the Numbers Are Getting Worse The pharmaceutical revenue cliff is not a metaphor. It is

The pharmaceutical industry spent roughly $2.3 billion and 12 years, on average, bringing a single new molecular entity to market

Every year, pharmaceutical companies abandon thousands of patents. They miss maintenance fee deadlines. They fail to validate patents in markets